Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

L. Krug · SciRah

Researcher profile · Semantic Scholar

L. Krug

Share profile

L. Krug — researcher profile on SciRah

h-index: 60
Works: 225
Citations: 16K

Most-cited papers

The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer
P. Goldstraw, K. Chansky, J. Crowley, Ramón Rami-Porta +140 more
2016Journal of Thoracic Oncology4,240 citations Open access
Semantic Scholar
Malignant pleural mesothelioma.
David S. Ettinger, W. Akerley, H. Borghaei, Andy C. Chang +30 more
2012The Journal of the National Comprehensive Cancer Network500 citations Open access
Semantic Scholar
Non-Small Cell Lung Cancer, Version 6.2015.
D. Ettinger, D. Wood, W. Akerley, L. Bazhenova +33 more
2015The Journal of the National Comprehensive Cancer Network404 citations Open access
Semantic Scholar
Non-small cell lung cancer, version 2.2013: Featured updates to the NCCN guidelines
D. Ettinger, W. Akerley, H. Borghaei, Andrew C. Chang +31 more
2013356 citations Open access
Semantic Scholar
Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer
M. Pietanza, S. Waqar, L. Krug, A. Dowlati +20 more
2018Journal of Clinical Oncology341 citations Open access
Semantic Scholar
Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors
H. Yu, C. Sima, James Huang, S. Solomon +9 more
2013Journal of Thoracic Oncology329 citations Open access
Semantic Scholar
Non-small cell lung cancer.
D. Ettinger, W. Akerley, H. Borghaei, Andrew C. Chang +32 more
2012The Journal of the National Comprehensive Cancer Network251 citations Open access
Semantic Scholar
Non-small cell lung cancer, version 2.2013.
D. Ettinger, W. Akerley, H. Borghaei, Andrew C. Chang +31 more
2013The Journal of the National Comprehensive Cancer Network230 citations
Semantic Scholar
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler, T. Karrison, D. Gandara, Charles Lu +13 more
2012Journal of Clinical Oncology220 citations Open access
Semantic Scholar
Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.
L. Krug, H. Kindler, H. Calvert, C. Manegold +15 more
2015The Lancet Oncology195 citations Open access
Semantic Scholar
Non-small cell lung cancer, version 1.2015.
D. Ettinger, D. Wood, W. Akerley, L. Bazhenova +33 more
2014The Journal of the National Comprehensive Cancer Network169 citations Open access
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology
J. Naidoo, C. Murphy, M. Atkins, J. Brahmer +13 more
2023Journal for ImmunoTherapy of Cancer166 citations Open access
Semantic Scholar
Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker
M. Pietanza, K. Kadota, K. Huberman, C. Sima +12 more
2012Clinical Cancer Research163 citations Open access
Semantic Scholar
Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.
A. Rimner, M. Zauderer, D. Gomez, P. Adusumilli +11 more
2016Journal of Clinical Oncology159 citations Open access
Semantic Scholar
Pleural Intensity-Modulated Radiation Therapy (IMRT) for Malignant Pleural Mesothelioma (MPM)
K. Rosenzweig, M. Zauderer, B. Laser, L. Krug +5 more
2012International Journal of Radiation Oncology, Biology, Physics153 citations Open access
Semantic Scholar
Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
J. Naidoo, M. Santos-Zabala, T. Iyriboz, K. Woo +14 more
2016Clinical Lung Cancer152 citations Open access
Semantic Scholar
The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass.
V. Rusch, E. Baldini, R. Bueno, M. de Perrot +8 more
2013Journal of Thoracic and Cardiovascular Surgery150 citations Open access
Semantic Scholar
A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
Gregory Riely, M. Johnson, C. Medina, N. Rizvi +7 more
2011Journal of Thoracic Oncology141 citations Open access
Semantic Scholar
BRIEF REPORT: SMALL CELL LUNG CANCERS IN PATIENTS WHO NEVER SMOKED CIGARETTES
A. Varghese, M. Zakowski, H. Yu, H. Won +8 more
2014Journal of Thoracic Oncology128 citations Open access
Semantic Scholar
The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers
H. Ujiie, K. Kadota, J. Nitadori, J. Aerts +6 more
2015Oncoimmunology125 citations Open access
Semantic Scholar
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
S. Dolly, A. Wagner, J. Bendell, H. Kindler +13 more
2016Clinical Cancer Research116 citations Open access
Semantic Scholar
Vinorelbine and Gemcitabine as Second- or Third-Line Therapy for Malignant Pleural Mesothelioma
M. Zauderer, S. Kass, K. Woo, C. Sima +2 more
2014Lung Cancer106 citations Open access
Semantic Scholar
Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable non-squamous non-small cell lung cancers
J. Chaft, V. Rusch, M. Ginsberg, P. Paik +13 more
2013Journal of Thoracic Oncology99 citations Open access
Semantic Scholar
Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology.
D. Ettinger, Gregory Riely, W. Akerley, H. Borghaei +31 more
2013The Journal of the National Comprehensive Cancer Network97 citations Open access
Semantic Scholar
A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer
P. Paik, C. Rudin, M. Pietanza, Andrew B. Brown +11 more
2011Lung Cancer93 citations Open access
Semantic Scholar
Clinical Characteristics of Patients with Malignant Pleural Mesothelioma Harboring Somatic BAP1 Mutations
M. Zauderer, M. Bott, Robert R. McMillan, C. Sima +3 more
2012Journal of Thoracic Oncology82 citations Open access
Semantic Scholar
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
M. Ladanyi, M. Zauderer, L. Krug, Tatsuo Ito +3 more
2012Clinical Cancer Research81 citations Open access
Semantic Scholar
Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
J. Chaft, A. Litvak, M. Arcila, Payal Patel +9 more
2014Clinical Lung Cancer70 citations
Semantic Scholar
Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma (MPM)
A. Billè, L. Krug, K. Woo, V. Rusch +1 more
2015Journal of Thoracic Oncology68 citations Open access
Semantic Scholar
A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer
M. Pietanza, A. Litvak, A. Varghese, L. Krug +10 more
2016Lung Cancer65 citations Open access
Semantic Scholar
Molecular Characteristics Predict Clinical Outcomes: Prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene
N. Rizvi, V. Rusch, W. Pao, J. Chaft +13 more
2011Clinical Cancer Research63 citations Open access
Semantic Scholar
Failure patterns after Hemithoracic Pleural Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma
A. Rimner, D. Spratt, M. Zauderer, K. Rosenzweig +6 more
2014International Journal of Radiation Oncology, Biology, Physics59 citations Open access
Semantic Scholar
Trial of a 5-Day Dosing Regimen of Temozolomide in Patients with Relapsed Small Cell Lung Cancers with Assessment of Methylguanine-DNA Methyltransferase
M. Zauderer, A. Drilon, K. Kadota, K. Huberman +11 more
2014Lung Cancer58 citations Open access
Semantic Scholar
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma
F. Shaikh, M. Zauderer, D. von Reibnitz, A. Wu +9 more
2017Journal of Thoracic Oncology57 citations Open access
Semantic Scholar
A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analog Peptide Vaccine, after Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
M. Zauderer, A. Tsao, T. Dao, K. Panageas +10 more
2017Clinical Cancer Research49 citations Open access
Semantic Scholar
Patterns of failure in limited-stage small cell lung cancer: implications of TNM stage for prophylactic cranial irradiation
A. Wu, A. Gillis, A. Foster, K. Woo +10 more
2017Radiotherapy and Oncology48 citations Open access
Semantic Scholar
Phase II Study of the Multitargeted Tyrosine Kinase Inhibitor XL647 in Patients with Non–Small-Cell Lung Cancer
M. Pietanza, S. Gadgeel, A. Dowlati, T. Lynch +13 more
2012Journal of Thoracic Oncology46 citations Open access
Semantic Scholar
VANTAGE 014: Vorinostat (V) in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial
L. Krug, H. Kindler, H. Calvert, C. Manegold +6 more
201131 citations
Semantic Scholar
Real-World Clinical Impact of Immune Checkpoint Inhibitors in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer After Platinum Chemotherapy.
L. Schwartzberg, B. Korytowsky, J. Penrod, Ying Zhang +3 more
2019Clinical Lung Cancer30 citations Open access
Semantic Scholar
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma.
L. Krug, A. Wozniak, H. Kindler, R. Feld +13 more
2014Lung Cancer30 citations
Semantic Scholar
Novel Therapies in Phase II and III Trials for Malignant Pleural Mesothelioma
M. Zauderer, L. Krug
2012The Journal of the National Comprehensive Cancer Network28 citations Open access
Semantic Scholar
Phase II Study of Arginine Deprivation Therapy With Pegargiminase in Patients With Relapsed Sensitive or Refractory Small-cell Lung Cancer.
P. Hall, N. Ready, A. Johnston, J. Bomalaski +4 more
2020Clinical Lung Cancer27 citations Open access
Semantic Scholar
Toxicity of initial chemotherapy in older patients with lung cancers
M. Zauderer, C. Sima, B. Korc-Grodzicki, M. Kris +1 more
2012Journal of Geriatric Oncology21 citations Open access
Semantic Scholar
Phase II Multicenter Trial of Voreloxin as Second-Line Therapy in Chemotherapy-Sensitive or Refractory Small Cell Lung Cancer
L. Krug, J. Crawford, David S. Ettinger, G. Shapiro +7 more
2011Journal of Thoracic Oncology20 citations Open access
Semantic Scholar
A multi-center, randomized, double-blind phase II study comparing temozolomide (TMZ) plus either veliparib (ABT-888), a PARP inhibitor, or placebo as 2nd or 3rd-line therapy for patients (Pts) with relapsed small cell lung cancers (SCLCs).
M. Pietanza, L. Krug, S. Waqar, A. Dowlati +15 more
201617 citations
Semantic Scholar
Small cell and neuroendocrine tumors of the lung
M. Pietanza, L. Krug, A. Wu, M. Kris +2 more
201516 citations
Semantic Scholar
Phase I study of intra-pleural administration of GL-ONC1, an oncolytic vaccinia virus, in patients with malignant pleural effusion.
L. Krug, M. Zauderer, P. S. Adusumili, E. McGee +5 more
201515 citations
Semantic Scholar
MA11.07 Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
L. Byers, L. Krug, S. Waqar, A. Dowlati +22 more
201714 citations Open access
Semantic Scholar
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
M. Hellmann, J. Chaft, V. Rusch, M. Ginsberg +14 more
2013Cancer Chemotherapy and Pharmacology14 citations Open access
Semantic Scholar
Pralatrexate with Vitamin Supplementation in Patients with Previously Treated, Advanced Non-small Cell Lung Cancer: Safety and Efficacy in a Phase 1 Trial
C. Azzoli, J. Patel, L. Krug, Vincent Miller +10 more
2011Journal of Thoracic Oncology13 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Kris×25
Invite
M. Kris — researcher profile on SciRah
Gregory Riely×15
Invite
Gregory Riely — researcher profile on SciRah
M. Pietanza×15
Invite
M. Pietanza — researcher profile on SciRah
M. Zauderer×14
Invite
M. Zauderer — researcher profile on SciRah

×13

Invite

V. Rusch — researcher profile on SciRah

Invite

W. Travis — researcher profile on SciRah

Invite

C. Sima — researcher profile on SciRah

Invite

K. Woo — researcher profile on SciRah

M. Ginsberg×10

Invite

M. Ginsberg — researcher profile on SciRah

Invite

C. Azzoli — researcher profile on SciRah

Invite

C. Rudin — researcher profile on SciRah

Invite

N. Rizvi — researcher profile on SciRah